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Abstract: Triple-negative breast cancer (TNBC) remains the poorest-prognosis breast cancer 
(BC) subtype. Gene expression profiling has identified at least six different triple-negative 
subtypes with different biology and sensitivity to therapies. The heterogeneous nature of TN 
tumors may justify the difficulty in treating this BC subtype. Several targeted agents have been 
investigated in clinical trials without demonstrating a clear survival benefit. Therefore, systemic 
chemotherapy remains the cornerstone of current clinical practice. Improving the knowledge of 
tumor biology is mandatory for patient management. In stages II and III, neoadjuvant systemic 
treatment is an effective option of care. The achievement of a pathological complete response 
represents an optimal surrogate for survival outcome as well as a test for tumor drug sensitiv-
ity. In this review, we provide a brief description of the main predictive biomarkers for tumor 
response to systemic treatment. Moreover, we review the treatment strategies investigated for 
TNBCs in neoadjuvant settings focusing on experimental drugs such as immunotherapy and 
poly [ADP-ribose] polymerase inhibitors that hold promise in the treatment of this aggressive 
disease. Therefore, the management of TNBC represents an urgent, current, unmet need in daily 
clinical practice. A key recommendation is to design biology-driven clinical trials wherein TNBC 
patients may be treated on the basis of tumor molecular profile.
Keywords: triple-negative breast cancer, neoadjuvant chemotherapy, BRCA, platinum, immu-
notherapy, PARP-1 inhibitors
Introduction
Currently, the treatment of patients with triple-negative breast cancer (TNBC) is the 
biggest challenge in the breast cancer (BC) scenario. TNBCs are defined by the absence 
of both hormone (estrogen and progesterone) receptors and HER2 overexpression.1 
TNBCs represent a heterogeneous group of BCs with different treatment sensitivity and 
prognosis. Preclinical studies have identified at least six different molecular subtypes: 
two basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a 
mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR).2
In the early stages, the use of neoadjuvant systemic treatment (NST) is the standard 
of care in TNBCs. Patients who achieve a pathological complete response (pCR) with 
primary therapy have improved survival outcomes.3,4 Standard neoadjuvant regimens 
include anthracyclines, taxanes, and cyclophosphamide.5,6 Platinum-based chemother-
apy has been proposed but is not yet recommended by available guidelines. Different 
systemic treatment options have been investigated besides the use of chemotherapy.7–12 
However, there are no approved targeted therapies for TNBC in the neoadjuvant  setting, 
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although many different drugs have been studied and still 
others are currently being tested.
Clearly, there is a major need to better understand the 
characteristics and the clinical behavior of TNBCs with an 
aim to develop effective treatments for this BC subtype. The 
identification of molecular targets is essential for the design 
of clinical trials that investigate new treatment strategies. 
In this article, we review the literature on the use of NST in 
TNBCs. We focus on the molecular markers able to predict 
response/resistance to therapies. Moreover, we review the 
recent data on experimental drugs tested, and discuss find-
ings concerning immunologic checkpoint inhibitors in this 
population. The main, ongoing clinical trials conducted in 
this field are reported as well.
Predictive factors of response/resistance 
to neoadjuvant treatment
The known, investigated, predictive factors of response/resis-
tance to NST in patients with TNBC are shown in Figure 1 
and listed further.
Breast-related cancer antigen 1
TNBCs are likely to be breast-related cancer antigen 1 
(BRCA1) mutation carriers or to have gene expression 
profiles similar to BRCA1-deficient tumors.13 BRCA genes 
play an important role in DNA double-strand break repair, 
 contributing to the maintenance of DNA stability.14 Approxi-
mately 20% of all TNBCs show loss or inactivation of BRCA 
genes, resulting in an inefficient repair mechanism.15,16 
Besides a mutation in BRCA1/BRCA2, hypermethylation 
of both – the BRCA1 promoter and Fanconi anemia gene 
(FANCF) – result in a BRCA-like phenotype (also called the 
“BRCAness” tumors). The BRCA status is considered a pre-
dictive factor of response to chemotherapy and poly [ADP-
ribose] polymerase (PARP) inhibitory agents. With regard to 
chemotherapy, tumor cell lines lacking functional BRCA1 or 
2 have increased sensitivity to DNA cross-linking agents such 
as platinum and to DNA-damaging chemotherapy agents such 
as anthracycline (Table 1).17 In two clinical studies conducted 
in TNBC patients treated with neoadjuvant single-agent 
cisplatin, pCR rates in BRCA-mutated women were 100% 
and 83%, respectively.15,18 Moreover, a significant difference 
in pCR rates has been found between BRCA1-mutated and 
BRCA1-wild-type women treated with anthracycline and 
taxane regimens (57.1% vs 29%; p < 0.001).16 On the other 
hand, preclinical evidence has shown a negative correlation 
between the BRCA1 mutation and taxane sensitivity due to 
the loss of a pro-apoptotic pathway activated in response to 
taxane-induced DNA damage.19 Furthermore, the increased 
sensitivity to DNA double-strand break agents has been 
confirmed in BRCA-like tumors that have a homologous 
recombination deficiency (HRD) similar to BRCA-mutated 
Figure 1 Triple negative breast cancer (TNBC) molecular subtypes classified according to gene expression and the main involved pathways. Each of these subclasses show 
varying pathological complete response (pCR) rates following standard neoadjuvant chemotherapy. Promising therapies for every molecular subtype have been suggested.
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Neoadjuvant treatments in triple-negative breast cancer
ones. A pooled analysis of six phase II trials conducted in 
TNBC patients treated with platinum demonstrated that 
patients with a high HRD score had an increased pCR rate 
compared to HR-non-deficient patients (53% vs 18%) regard-
less of the BRCA mutation status.20
Molecular subtypes
Lehmann et al analyzed gene expression profiles in 587 
TNBCs and identified six different subtypes: BL1, BL2, 
IM, M, MSL, and LAR.21 BL tumors are characterized 
by a high frequency of chromosomal rearrangements, 
genomic instability, and BRCA1 or BRCA2 mutations. In 
particular, BL1 tumors are usually enriched in cell-cycle 
and DNA-damage-response genes that justify their high 
sensitivity to DNA-damaging agents such as platinum. 
In contrast, BL2 cancers frequently overexpress growth 
factor receptors, such as epidermal growth factor recep-
tor (EGFR), IGF1R, and myoepithelial markers with low 
probability of tumor response to chemotherapy.21 More 
recent data, presented at the San Antonio Breast Cancer 
Symposium (SABCS) 2016, confirmed how BL1 tumors 
were likely to achieve a higher pCR rate compared to 
other TNBC subtypes (38% vs 20%, p = 0.015).22 Both M 
and MSL are enriched in pathways associated with EMT 
(epithelial–mesenchymal transition) and cell motility. This 
BC subtype frequently presents PI3KCA-activating muta-
tions. According to genomic expression, mesenchymal 
tumor cells have displayed responses to dasatinib (abl/src 
inhibitor) and a PI3K/mTOR inhibitor. The LAR subtype 
cells express androgen receptors with sensitivity to an 
AR antagonist such as bicalutamide. Finally, IM tumors 
are enriched in genes involved in immune cell processes 
and may be considered the more promising subtypes for 
immunotherapies.21 This molecular classification seems to 
have not only a predictive value but also a prognostic one. 
A significant difference in relapse-free survival (RFS) has 
been found among molecular subtypes. In particular, LAR 
tumors show a decreased RFS compared with the BL1, IM, 
and MSL subtypes (HR = 2.9, 3.2, and 10.5, respectively; 
p < 0.05). There were no reported significant differences in 
terms of distant-metastasis-free survival (DMFS).21
epidermal growth factor receptor
The EGFR is a transmembrane tyrosine kinase receptor 
localized on the cell surface that induces cell proliferation, 
angiogenesis, and apoptosis inhibition.23–25 EGFR abnor-
malities are reported in 27%–57% of TNBCs.26 Clinical data 
suggested a possible predictive and prognostic value of the 
EGFR. A retrospective analysis of 117 patients, 28 of whom 
had a TNBC, showed that EGFR expression was related to a 
worse response to anthracycline-based NST and poor overall 
prognosis (p = 0.03).27 Moreover, in a multivariate analysis of 
a retrospective study conducted in 287 women with TNBCs, 
EGFR overexpression was a significant independent prog-
nostic factor for relapse (31% in EGFR-positive vs 16.2% in 
EGFR-negative patients).28 Preclinical data showed how the 
use of anti-EGFR antibodies can decrease antitumor activity 
by downregulation of EGFR (endocytosis and degradation) 
and limit cell migration.29 Based on this evidence, a multi-
center, prospective, single-arm phase II study was conducted 
among 60 women with stages II and IIIa TNBC, with an aim to 
investigate the rule of panitumumab (anti-EGFR antibody) in 
addition to NST (fluorouracil+epirubicin + cyclophosphamide 
[FEC] followed by docetaxel).12 The pCR rates were 46.8% 
in breast and nodes, and 55.3% in the breast only. EGFR 
expression was confirmed as a predictive factor for response 
to chemotherapy plus panitumumab. A positive trend for pCR 
was shown in EGFR overexpressed BC (58% vs 28%, p = 
0.079), suggesting a potential benefit of anti-EGFR therapy 
plus chemotherapy in this subgroup of patients.12
Tumor-infiltrating lymphocytes
Since the last decade onward, the immune system has been 
under investigation as a possible target in the management 
of different cancer subtypes. Tumor-infiltrated lymphocytes 
(TILs) have been identified in both tumor and stromal tissues. 
Intratumoral TILs (It-TILs) are lymphocytes that have a direct 
interaction with cancer cells, whereas stromal TILs (Str-TILs) 
Table 1 pCR rate reported in published clinical trials in TNBC BRCA-mutated (BRCA mt) patients




Treatment pCR definition pCR BRCA  
mt %
Byrsky et al15 Phase ii 107 82 Cisplatin ypT0/is ypN0 61
wang et al16 Retrospective 956 68 Anthracycline +/- taxane/taxane ypT0/is ypN0 53.8
Silver et al18 Phase ii 28 2 Cisplatin ypT0/is ypN0 100
Telli et al20 Pooled analysis 93 19 Carboplatin + gemcitabine + iniparib ypT0/is ypN0 47
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are lymphocytes localized in the peripheral stromal area. 
Considering BC subtypes, TNBCs have the highest tumor 
TIL expression (~20%) compared to other BC subtypes.30,31 
In particular, the IM subtype of TNBC is characterized by 
high presence of immune cells, antigen presentation, and 
activation of immune pathways.21 Clinical data suggested a 
predictive role of TILs in terms of pCR in patients treated 
with NST, mainly with platinum regimens.32–34 A prospec-
tive evaluation of TILs in the GeparSixto trial found that 
lymphocyte-predominant (LP) BC, defined as tumors with 
lymphocytic infiltrate greater than 50%, were more likely to 
achieve pCR as compared to non-LP BCs (59.9% vs 33.8%; 
p < 0.001).35 The addition of carboplatin to anthracycline and 
taxane in LPBCs further increased the pCR rate up to 75% 
(p = 0.002).35 The predictive role of TILs primarily suggested 
by some small retrospective data36–39 was confirmed by the 
large meta-analysis present at the SABCS 2016, where a 
total of 3,771 tumors from the clinical Gepar studies (Gepar-
Duo, GeparTrio, GeparQuattro, GeparQuinto, GeparSixto, 
and GeparSepto) were evaluated for the presence of TIL.40 
These results suggest TILs are a strong predictive marker 
for response to NST in all BC subtypes.40 This predictive 
value was translated into a survival benefit in the TNBCs 
group. The presence of TILs in residual tumor disease after 
primary chemotherapy seems to be related to more favorable 
long-term outcomes as well.40 Another retrospective cohort 
of 278 patients with TNBCs correlated TIL presence with a 
risk reduction of metastasis and death. The major prognostic 
relevance of TILs was found in patients with residual tumor 
>2 cm and/or node metastasis.33 These authors hypothesized 
a possible use of TILs for selecting patients with high risk of 
relapse after NST. A comparison between TIL expression in 
the BC tissue before and after chemotherapy administration 
was also undertaken, showing that chemotherapy switches 
low-TIL tumors into high-TIL tumors.33 Cytotoxic drugs are 
able to modify the tumor microenvironment, thus inducing 
cross-presentation of new peptide antigens, dendritic cell 
activation, and specific cytotoxic T cells.41–46 This evidence 
supports the idea that the efficacy of immunotherapy may be 
amplified by chemotherapy.33 Based on these data, several 
neoadjuvant trials studying the addition of immunotherapy 
to chemotherapy in TNBC patients are ongoing.
Focusing on the subsets of TILs, there are two different 
functional components: cytotoxic CD8+ T cells and regula-
tory FOXP3+ T cells. CD8+ TILs lead to tumor cell death 
through linking foreign antigens on tumor cells.47–49 In 
contrast, FOXP3+ TILs, have a critical role in suppressing 
antitumor immunity. Miyashita et al published a  retrospective 
multicenter study which evaluated CD8+ TIL, FOXP3+ 
TIL, and CD8/FOXP3 ratios before and after NST in TNBC 
 tissue.50,51 The results showed that patients with high CD8+ 
TILs had a smaller residual tumor (≤2 cm) than patients with 
low-TILs (p = 0.005).52 No association between residual 
tumor size and FOXP3+ TILs or the CD8/FOXP3 ratio was 
found. Both high CD8+ levels and higher CD8/FOXP3 ratio 
were associated with improved recurrence-free survival and 
breast-cancer-specific survival (p < 0.0001).52 These data have 
been confirmed in a large meta-analysis, where the absence 
of both CD8+ TILs and FOXP3+ TILs were associated with 
worse disease-free survival (DFS) and overall survival (OS).53
PD-1/PD-L1
The programmed cell death protein 1 (PD-1) is expressed 
on the surface of T cells, and is an immune checkpoint that 
inhibits T-cell effector function within tissues. PD-1 has two 
ligands known as PD-L1 and PD-L2; in particular, PD-L1 
expression is present in several tumor types. The ligand 
between PD-L1 and PD-1 on the surface of a lymphocyte 
blocks the immune response against cancer cells.54 The 
presence of PD-L1 in the tumor microenvironment seems 
to indicate an adaptive immune resistance to endogenous 
antitumor activity.55 With regard to BC, PD-L1 expression 
has been found in 50% of all BC subtypes. Its expression was 
mainly associated with high histological grade and negative 
hormone receptors.56 The first study to investigate PD-L1 
expression (defined as cell-surface membrane staining >5%) 
conducted in BC found a higher PD-L1 expression in TNBCs 
as compared to non-TNBCs (p < 0.001).57 In a large study, 
PD-L1 expression was found to be positive in 64% of the cell 
membrane, 80% of cytoplasm, and in 93% of tumor stroma 
in TNBCs. In these cases, PD-L1 expression was related to 
better survival outcomes.58 Despite this evidence, it is well 
known that PD-L1 is a dynamic marker that changes rapidly 
over time. The tumor microenvironment, as well as systemic 
cytotoxic treatment and radiation, influence the immune 
system thereby determining PD-L1 expression changes. 
Therefore, a biopsy at one time point may not accurately 
reflect the real tumor microenvironment. For this reason, 
tumor PD-L1 expression can be considered to only reflect 
an immune-active microenvironment with activated T cells 
in an immunocompetent host, and is not an appropriate pre-
dictive biomarker to select patients for immunotherapeutic 
treatment.59 Clinical data on the use of anti-PD-1 or anti-
PD-L1 antibodies in different cancer subtypes showed how 
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Neoadjuvant treatments in triple-negative breast cancer
Androgen receptor
The LAR TNBC is characterized by high androgen receptor 
(AR) and luminal cytokeratin expression.21 Overall, ARs 
are expressed in 12%–36% of TNBCs.65–68 LAR BCs are 
usually associated with low grade and tumor size, mainly 
present in postmenopausal women.69 Significantly better 
DFS, RFS, and OS have been reported on comparing LAR 
to non-LAR TNBCs.21,70,71 AR expression seems to be a 
predictive biomarker for tumor resistance to chemotherapy. 
When considering neoadjuvant anthracycline/taxane-based 
chemotherapy, LAR tumors have the lowest pCR rate (0%–
10%) as compared to other TNBCs.21,70,71 On the other hand, 
AR expression could be considered a predictive marker for 
tumor response to antiandrogen therapies. Several preclinical 
studies demonstrated the sensitivity of the LAR cell line to 
antiandrogen medication.21 Xenograft studies with the use 
of bicalutamide or enzalutamide support the hypothesis that 
anti-androgen therapy may be useful for such tumors.21,72 In 
the metastatic setting, clinical evidence suggested the effi-
cacy of these two drugs in terms of clinical benefit rate and 
progression-free survival (PFS) in patients with AR-positive 
BC.10,11 A phase IIB study (NCT02689427) conducted in AR-
positive TNBCs treated with enzalutamide plus placlitaxel in 
the neoadjuvant setting is currently ongoing.73
Tumor suppressor gene p53
In the subgroups of TNBCs, BL tumors often overexpress 
genes that codify for proteins involved in cell-cycle and DNA-
damage response. p53 is a tumor suppressor protein which 
plays a key role in apoptosis in response to DNA damage. 
The complex p53–p63 inhibits the activity of Rab7 – a pro-
tein involved in the degradation of EGFR which induces cell 
proliferation, angiogenesis, and inhibits apoptosis.74 Available 
evidence suggests a possible relationship between p53 and 
BRCA1, with an increased frequency of p53 mutations in 
BRCA-related tumors.3 p53-mutated tumors are character-
ized by aggressive tumor biology with poor differentiation, 
high tumor grade, and invasiveness.75,76 p53 overexpression 
seems to be associated with a worse prognosis in terms of 
OS and DFS, but with higher chemotherapy sensitivity.75,77–80 
With regard to TNBC, many studies have demonstrated that 
p53 is mutated in the majority (60%–88%) of these tumors.81 
The most frequent p53 mutations in TNBC are missense 
mutations with single-amino-acid substitution.82 Bidard et al 
showed that a p53+/TNBC tumor treated with anthracyclines/
alkylating agents had a higher probability of achieving pCR 
compared to other p53+/BC subtypes (p < 0.001).83
Chemotherapy agents in the neoadjuvant 
setting
Cytotoxic chemotherapy is the backbone of TNBC treatment. 
In a large study evaluating the neoadjuvant setting, Liedtke 
et al evaluated the response to different neoadjuvant chemo-
therapy regimens in 1,118 patients with early-stage BC treated 
with different drugs.84 In the subgroup of TNBC, the pCR rate 
was higher as compared to that among non-TNBC patients 
(22% vs 11%; p = 0.034), independent of chemotherapy 
regimens.84 Actually, the standard of care in the neoadjuvant 
setting for TNBC is sequential anthracycline–taxane-based 
chemotherapy.5 The pCR rate of these regimens ranges from 
28% to 36%.84–86 To increase the rate of response, different 
chemotherapeutic strategies have been tested (Table 2).
weekly nanoparticle-albumin-bound 
paclitaxel (nab-paclitaxel) instead of 
weekly paclitaxel
Available evidence suggests a possible clinical benefit in terms 
of tumor response due to the introduction of nab-paclitaxel 
instead of weekly paclitaxel. In the phase III GeparSepto 
study, pCR was reached in 48% of TNBC patients treated 
with weekly nab-paclitaxel 150 mg/m2 versus 26% of patients 
treated with weekly paclitaxel 80 mg/m2 (p = 0.00027).87 Of 
note, the dose of nab-paclitaxel was reduced from 150 to 
125 mg/m2 due to the higher incidence of severe sensory neu-
ropathy, without affecting the treatment efficacy.87 A phase III 
trial (ETNA study) first presented at the the American Society 
of Clinical Oncology (ASCO) 2016 showed a higher rate of 
response in the nab-paclitaxel arm compared to the paclitaxel 
one (41.3% vs 35.5%; p-value not statistically significant).88 
Similar pCR rates have been reported by Kuwayama et al in a 
subgroup of TNBC patients treated with four cycles of weekly 
nab-paclitaxel 100 mg/m2.89 Moreover, early results from the 
WSG-ADAPT trial showed a possible advantage in terms of 
pCR by adding nab-paclitaxel, rather than gemcitabine, to 
carboplatin (44.5 vs 28.4, p = 0.004).22 Several clinical trials 
are currently further investigating the role of nab-paclitaxel 
in this setting.
Addition of platinum agents
The hypothesis of an increased efficacy of platinum agents 
in TNBC is based on the fact that these tumors often show 
functional BRCA1 alterations that increase the sensitivity to 
cross-linking agents.90 Clinical evidence suggests that the 
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the rate of tumor response, but this clinical advantage has 
not been clearly translated into a survival benefit. Platinum-
based chemotherapy has been investigated in several stud-
ies, but the best platinum agent, the ideal combination, or 
the best sequence with other chemotherapy agents remains 
unknown.91–93 In particular, a retrospective study that com-
pared docetaxel with cisplatin or carboplatin showed the 
superiority of cisplatin in terms of OS (hazard ratio [HR] 
0.49, p = 0.007) and PFS (HR 0.40, p = 0.018) with a quite 
good tolerability profile.92 This difference between the two 
platinum agents was not confirmed in another large pooled 
analysis.94 More consistent are the data on the increased 
response rate due to the addition of platinum to standard che-
motherapy, mainly in anthracycline-free regimens.95–98 The 
subgroup analysis of five clinical trials, conducted in TNBC 
patients treated with neoadjuvant platinum-containing thera-
pies combined with taxanes, showed a pCR rate ranging from 
33% to 67%.95–99 These data are in accordance with the results 
from the GeparSixto study, where the addition of carboplatin 
to anthracycline or taxane-based therapy improved the pCR 
from 36.9% to 53.2%.100 A large meta-analysis (included 
six randomized controlled trials and 22 retrospective or 
prospective studies) strongly confirmed the advantage due to 
platinum addition in both the objective response rate (86.7%) 
and the pCR rate (48.4%).94 Data presented at the ASCO 
2017 further underline the advantage in tumor response 
in patients treated with carboplatin/docetaxel compared to 
taxane–anthracycline-based regimen.101 Data from the WSG-
ADAPT TN trial suggested that immune marker gene expres-
sion (CD8, PD1, and PFDL1) and high-proliferation markers 
(proliferation score,  Prosigna Breast Cancer Prognostic Gene 
Signature Assay [PAM-50] risk-of-recurrence [ROR] score, 
MKI67, CDC20, NUF2, KIF2C, CENPF, EMP3, and TYMS) 
were positively associated with pCR in carbo-containing 
chemotherapy regimens.22 In all of these reported studies, 
the addition of carboplatin increased hematological and 
non-hematological toxicity, with consequent frequent dose 
reduction. Nowadays, the increased toxicity and the lack of 
clear demonstrated long-term survival benefit due to plati-
num addition constitute reasons why platinum agents are not 
included in the standard of care for TNBC in the neoadjuvant 
setting. Despite this, the evidence that the pCR is strongly 
associated with OS in TNBC is an argument often used by 
the physicians to justify the addition of carboplatin to NST 
in clinical practice. Several phase III trials are ongoing and 
may provide more information on this topic.
eribulin in addition to carboplatin
Eribulin is a non-taxane microtubule inhibitor that causes 
irreversible cell-cycle blockade at the G2–M phase. Eribulin is 
approved in the management of metastatic BC after at least two 
treatment regimens with an anthracycline and a taxane, but its 
role in other settings is currently under investigation. A phase 
II clinical trial conducted in 30 TN early-stage BC patients 
investigated the response rate to 3-weekly carboplatin AUC 
6 plus eribulin 1.4 mg/m2 (days 1 and 8 every 21 days).102 In 
Table 2 pCR rate due to different chemotherapy regimens reported in published clinical trials in TNBC patients
Study Study design TNBC n Treatment pCR definition pCR %
Anthracycline/taxane    
Liedtke et al84 Prospective 255 Taxane + anthracycline + cyclophosphamide + fluorouracil ypT0/is ypN0 28
von Minckwitz et al85 Pooled analysis 742 Anthracycline + taxane ypT0/is ypN0 34
von Minckwitz et al86 Pooled analysis 911 Anthracycline + taxane ypT0/is ypN0 35.8
Carboplatin    
Sikov et al95 Phase ii 12 Paclitaxel + carboplatin ypT0/is ypN0 67
Chen et al96 Phase ii 17 Paclitaxel + carboplatin ypT0/is ypN0 33.3
Roy et al97 Phase ii 9 Docetaxel + carboplatin ypT0 ypN0 44
Chang et al98 Phase ii 11 Docetaxel + carboplatin ypT0/is ypN0 55
Campos Gomez et al99 Phase ii 35 Doxorubicin + cyclophosphamide → docetaxel + 
carboplatin
ypT0/is ypN0 50
von Minckwitz et al100 Phase iii 158 Paclitaxel + liposomal doxorubicin + bevacizumab + 
carboplatin
ypT0 ypN0 53.2
Nab-paclitaxel    
Untch et al87 Phase iii 139 Nab-paclitaxel → epirubicin + cyclophosphamide ypT0 ypN0 48
Gianni et al88 Phase iii 219 Nab-paclitaxel + anthracycline (investigator choice) ypT0/is ypN0 41.3
Gluz et al22 Phase ii 61 Nab-paclitaxel + carboplatin ypT0/is ypN0 49.2
Kuwayama et al89 Phase ii 54 Nab-paclitaxel + anthracycline + cyclophosphamide + 
fluorouracil
ypT0/is ypN0 30
Eribulin      
Kaklamani et al102 Phase ii 30 Carboplatin + eribulin ypT0/is ypN0 43
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Neoadjuvant treatments in triple-negative breast cancer
total, 80% of enrolled patients had a clinical complete or partial 
response, and 43% achieved pCR.102 Moreover, another phase 
II international trial (NCT01372579) is ongoing with the aim 
to investigate the efficacy of a preoperative eribulin mesylate 
and carboplatin combination in stages I–III TNBCs.103
Dose-dense chemotherapy
Dose-dense (DD) chemotherapy aims to achieve maximum 
tumor death by delivering therapeutic drugs over a shorter 
duration. The efficacy of DD systemic treatment was mainly 
investigated in the adjuvant setting. A recent meta-analysis 
including a total of eight phase III trials (17,188 randomized 
women) showed that patients treated with DD chemotherapy 
had better OS and DFS than those on the conventional sched-
ule. In particular, statistically significant OS benefit was 
observed in patients with hormone-receptor-negative tumors 
(HR 0.8, p = 0.002).104 Data from the DD schedule in the 
neoadjuvant setting are less consistent.105 Published clinical 
trials included women treated with outdated regimens and/
or schedules; there are no data regarding the benefit of DD 
anthracycline–taxane-based primary chemotherapy. Conven-
tionally, in clinical practice, results from DD adjuvant che-
motherapy studies are applied in the neoadjuvant setting too.
Targeted agents tested in neoadjuvant 
setting
Table 3 summarizes the main clinical trials where targeted 
agents have been evaluated in addition to NST.
PARP-1 inhibitors
PARP-1 is an enzyme known to be involved in the base-
excision repair pathway, which plays a key role in the repair 
of single-stranded DNA breaks.106,107 During the last decade, 
drugs able to  interfere with the DNA-damage-repair systems 
and to induce a synthetic lethality, named PARP inhibitors 
(such as iniparib, olaparib, and veliparib), have been developed. 
The main evidence is in the metastatic setting, where PARP 
inhibitors have been tested as single agents and in combination 
with chemotherapy.9,108 The best results in terms of efficacy 
emerged from combination with cisplatin or carboplatin, as 
well as with topotecan and temozolamide, with response rates 
in BRCA-related BC of up to 73%.109–112 Considering the use of 
PARP inhibitors in the neoadjuvant setting, a single-arm phase 
II study showed efficacy in terms of pCR of gemcitabine com-
bined with carboplatin and iniparib in TNBC.113 In this study, 
the presence of HRD was associated with higher response 
rates, regardless of BRCA 1/2 mutational status.113 Results 
from the veliparib and carboplatin arm in the I-SPY-2 trial, a 
multicenter, adaptively randomized trial, reported 51% pCR 
in the experimental arm versus 26% in the standard regimen. 
Considering adverse events, hematological side effects were 
higher in the veliparib–carboplatin group than in the control 
arm.114 No difference in the pCR rate due to the addition of 
velaparib to carboplatin–paclitaxel, followed by doxorubicin 
plus cyclophosphamide, has been reported in a phase III study 
presented by the German Breast Group at the ASCO 2017.115 
A phase II study of neoadjuvant talazoparib monotherapy in 
BRCA-associated BC is ongoing at the MD Anderson Cancer 
Center.116 Considering these preliminary controversial results, 
PARP inhibitors are still under investigation.
Anti-angiogenic agents
Bevacizumab is a humanized monoclonal antibody that 
targets the main isoforms of circulating vascular endothelial 
Table 3 pCR rate TNBC patients treated with chemotherapy plus targeted agents
Study Study design TNBC n Treatment pCR definition pCR %
Bevacizumab      
Gerber et al7 Phase iii 323 epirubicin + cyclophosphamide → docetaxel + bevacizumab ypT0 ypN0 39
earl et al121 Phase iii 119 Bevacizumab + docetaxel → epirubicin + cyclophosphamide ypT0/is ypN0 45
Sikov et al122 Phase ii 226 Paclitaxel → doxorubicin + cyclophosphamide + bevacizumab ypT0/is* 59
Guarneri et al124 Phase ii 44 Paclitaxel + carboplatin + bevacizumab ypT0/is ypN0 50
Kim et al125 Phase ii 45 Carboplatin + docetaxel + bevacizumab ypT0/is ypN0 42
Nahleh et al126 Phase ii 32 Nab-paclitaxel + bevacizumab → adriamycin + cyclophosphamide ypT0/is ypN0 59
Mrózek et al127 Phase ii 12 Nab-paclitaxel + carboplatin + bevacizumab ypT0 ypN0 50
PARP-inhibitor      
Telli et al113 Phase ii 80 Gemcitabine + carboplatin + iniparib§ ypT0/is ypN0 36
Rugo et al114 Phase ii 54 velparib + carboplatin → doxorubicin + cyclophosphamide ypT0 ypN0 51
Immunotherapy      
Schmid et al128 Phase iB 20 Pembrolizumab + nab-paclitaxel → pembrolizumab + doxorubicin 
+ cyclophosphamide ± carboplatin
ypT0/is ypN0 85
Nanda et al129 Phase ii 21 Paclitaxel + pembrolizumab → doxorubicin + cyclophosphamide ypT0/is ypN0 71
Note: *pCR in breast only; §pCR rate in patients treated with six cycles of neoadjuvant treatment.
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growth factor (VEGF), resulting in the inhibition of angio-
genesis, cell tumor growth, and cell survival.117 Bevacizumab 
use has been investigated in both advanced and early-stage 
BC treatments, showing an increased response rate – mainly, 
in TNBC patients.84,100,118–120 When added to chemotherapy 
in preoperative treatment, the pCR rate ranges from 40% to 
59% independent of the chemotherapy regimen administered. 
The phase III GeparQuinto trial included 663 TNBC patients 
treated with epirubicin and cyclophosphamide followed by 
docetaxel with or without bevacizumab, and showed a pCR 
rate of 39.3% in the bevacizumab arm versus 27.9% in the 
control arm (p = 0.021).7 The advantage in response rate due 
to the addition of bevacizumab has been demonstrated in two 
other large trials. The first one is the multicenter British phase 
III study (ARTemis), where 781 patients were randomized 
to receive bevacizumab or placebo plus docetaxel followed 
by cyclophosphamide, 5-fluorouracil, and epirubicine.121 In 
the TNBC subgroup, bevacizumab provided an advantage 
in terms of pCR from 34% to 49%.121 The second one – the 
CALGB 40603/Alliance trial, conducted in 443 patients 
with stages II and III TNBC – confirmed the increase of 
tumor response in the bevacizumab group, independent 
of the chemotherapy regimen administered.122,123 Similar 
response rates have been found in two phase II trials: the 
Ca.Pa.Be study, where 44 TNBC women were treated with 
a combination of paclitaxel, carboplatin, and bevacizumab, 
and the KCSG BR-0905 trial, where 45 women were treated 
with bevacizumab, docetaxel, and carboplatin.124,125 The 
addition of bevacizumab to nab-paclitaxel was investigated 
in two phase II trials, showing an increase of response rate 
compared to bevacizumab plus paclitaxel or docetaxel.126,127 
In the first one, the SWOG S0800 trial, the combination of 
bevacizumab plus nab-paclitaxel, followed by DD doxoru-
bicin and cyclophosphamide, increased the pCR rate up to 
59% (p = 0.014).126 In the second one, 50% of TNBC patients 
treated with bevacizumab plus nab-paclitaxel and carbopla-
tin achieved pCR.127 With regard to safety profile, patients 
treated with bevacizumab experienced an increased number 
of immediate and delayed postoperative complications as well 
as neutropenia and hypertension.121,122 Nowadays, the use of 
bevacizumab in the neoadjuvant setting is still controversial 
and not recommended, mainly due to the lack of survival-
benefit evidence.
immunotherapy
The evidence that stimulating the immune cells might, there-
fore, be an option to increase response rates is the rationale for 
designing clinical trials with the addition of immunotherapy 
in the neoadjuvant setting. Preliminary results from the 
KEYNOTE-173 presented at the ASCO 2017 (nab-paclitaxel 
± carboplatin plus pembrolizumab, followed by cyclophos-
phamide and doxorubicin) suggested promising antitumor 
activity of pembrolizumab when combined with NST.128
The objective response rate before surgery was 100% in 
the pembrolizumab and carboplatin group versus 80% in the 
other experimental group (nab-paclitaxel + pembrolizumab); 
the pCR rate (yT0/Tis yN0) was 90% versus 60%, respec-
tively.128 Similar results have been reported in the subgroup 
of patients treated with pembrolizumab in the I-SPY-2 trial.129 
Data presented at the ASCO 2017 were based on results 
observed in patients at high risk of relapse using upfront tumor 
profiling (including mammaPrint 70-gene signature test). 
Patients were treated with weekly paclitaxel for 12 weeks ± 
pembrolizumab, followed by anthracyclines.129 In the TNBC 
women, an absolute increase in the estimated pCR rate of 
40% was observed in the pembrolizumab arm (based on the 
estimated pCR rate of 60% with pembrolizumab plus stan-
dard therapy compared to 20% with standard NST alone).129 
Currently, two different strategies are under investigation to 
evaluate the real benefit of immunotherapy in early-stage 
TNBC: the addition of PD1/PD-L1 inhibitors to different NST 
regimens and the administration of PD1/PD-L1 inhibitors in 
the adjuvant setting in patients with residual BC disease after 
NST. In the first case, four studies are currently recruiting 
patients: the phase III NeoTRIPaPDL1 trial, a multicenter 
randomized study with patients treated with nab-paclitaxel 
plus carboplatin ± atezolizumab;130 the GeparNuevo trial, a 
phase II study of nab-paclitaxel ± durvalumab followed by 
epirubicin plus cyclophosphamide; and two other studies with 
nab-paclitaxel plus atezolizumab or durvalumab.131–133 With 
regard to the second strategy, two big clinical trials are now 
ongoing, both conducted in high-risk TNBC patients with 
residual disease after NST, randomized to receive 1 year of 
adjuvant pembrolizumab or avelumab versus observation.134,135 
The results of all these studies are awaited with high interest.
Conclusion
According to current international guidelines, in early-stage 
TNBC, the timing of treatment (pre- vs postoperative) has no 
effect on long-term outcomes. All chemotherapy strategies 
used in adjuvant treatment may also be used preoperatively. If 
a primary chemotherapy treatment is used, it is recommended 
to deliver all planned treatment without unnecessary breaks, 
irrespective of the magnitude of tumor response.136,137
In our opinion, NST should be the first option in the 
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Neoadjuvant treatments in triple-negative breast cancer
(when mastectomy is required due to tumor size), as well as 
in high-grade and high-proliferation-rate tumors. Despite 
the progress in our understanding of TNBC, anthracycline– 
taxane-based chemotherapy remains the standard of care 
for NST in all TNBC subtypes. Platinum agents, as well as 
PARP-inhibitor agents, provide pCR advantage in different 
clinical trials, mainly in BRCA-defense tumors, without 
demonstrating an improvement in survival benefit. At pres-
ent, there are no clear predictive biomarkers useful in clinical 
practice. The classification of TNBC using molecular pro-
file showed how TNBCs are a heterogeneous group which 
explains the lack of survival benefit of experimental drugs 
tested in several clinical trials. All of the available evidence 
suggests the necessity of design biology-driven clinical trials 
wherein TNBC patients may be treated on the basis of tumor 
molecular profile.
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